London School of Hygiene and Tropical Medicine, London, United Kingdom; Polio Eradication, World Health Organisation, Geneva, Switzerland.
Bill and Melinda Gates Foundation, Seattle, Washington, United States.
Vaccine. 2023 Apr 6;41 Suppl 1(Suppl 1):A122-A127. doi: 10.1016/j.vaccine.2022.02.050. Epub 2022 Mar 17.
To address the evolving risk of circulating vaccine-derived poliovirus type 2 (cVDPV2), Global Polio Eradication Initiative (GPEI) partners are working closely with countries to deploy an additional innovative tool for outbreak response - novel oral polio vaccine type 2 (nOPV2). The World Health Organization's (WHO) Prequalification program issued an Emergency Use Listing (EUL) recommendation for nOPV2 on 13 November 2020. The WHO's EUL procedure was created to assess and list unlicensed vaccines, therapeutics and diagnostics to enable their use in response to a Public Health Emergency of International Concern (PHEIC). nOPV2 was the first vaccine to receive an EUL, paving the way for other emergency vaccines. In this report, we summarise the pathway for nOPV2 roll-out under EUL.
为应对循环疫苗衍生脊髓灰质炎 2 型病毒（cVDPV2）不断变化的风险，全球根除脊髓灰质炎行动（GPEI）合作伙伴正与各国密切合作，部署一种新的创新工具来应对疫情——新型口服脊髓灰质炎 2 型疫苗（nOPV2）。世界卫生组织（WHO）于 2020 年 11 月 13 日发布了 nOPV2 的紧急使用清单（EUL）建议。WHO 的 EUL 程序旨在评估和列出未许可的疫苗、疗法和诊断方法，以使其能够用于应对国际关注的突发公共卫生事件（PHEIC）。nOPV2 是第一个获得 EUL 的疫苗，为其他应急疫苗铺平了道路。在本报告中，我们总结了 EUL 下 nOPV2 的推出途径。
